Form 4: Pfizer CEO Albert Bourla Reports Acquisition of Phantom Stock Units
SEC Form 4 Filing
Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 69 phantom stock units through the company's Supplemental Savings Plan.
Summary
- On October 10, 2024, Albert Bourla, Chairman and CEO of Pfizer Inc., acquired 69 phantom stock units.
- The acquisition was made through the Pfizer Supplemental Savings Plan (SSP).
- Each unit represents one phantom share of Pfizer common stock.
- The price of the phantom stock units was $29.34.
- Following the transaction, Bourla directly owns 679,059 derivative securities.
- These units are settled in cash upon separation from service and can be transferred into an alternative investment account at any time.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't convey any positive or negative sentiment about the company's performance or future prospects.
Industry Context
This filing is a routine disclosure of insider transactions, which are common for executives of publicly traded companies. It provides transparency into the executive's holdings and aligns their interests with those of the shareholders.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders.
- It provides transparency to shareholders regarding executive compensation and ownership.
Key Dates
| Date | Description |
|---|---|
| 10/10/2024 | Date of transaction: Albert Bourla acquired 69 phantom stock units. |
| 10/11/2024 | Date of report filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.